Authorization expectation for listed cytopathology CPT codes

Referenced cytopathology CPT codes (88108, 88112, 88172, 88173, 88177) listed in this policy may be subject to prior authorization and should be supported by documentation demonstrating medical necessity per the member’s benefit.

• Procedure codes: 88108, 88112, 88172, 88173, 88177

Prior authorization may apply to listed cytopathology CPT codes

Check the payer’s prior authorization requirements before submitting claims for cytopathology services coded with 88108, 88112, 88172, 88173, or 88177; these codes are explicitly referenced in the policy and may require authorization where applicable.

• Codes to verify for prior authorization: 88108, 88112, 88172, 88173, 88177

Core needle biopsy preferred over FNA for suspicious breast masses

When a tissue diagnosis is required for a suspicious breast mass, core needle biopsy is preferred over fine‑needle aspiration (FNA) because core biopsy has superior sensitivity, specificity, and provides correct histologic grading.

• FNA is a rapid technique but less accurate than core needle biopsy and cannot reliably distinguish in situ from invasive cancer; core biopsy is superior

Documentation and coding responsibilities

Providers are responsible for submission of accurate documentation of services performed and must code claims according to industry-standard coding guidelines; failure to follow coding/billing guidelines may result in denial or recoupment.

• Follow industry standards (CPT, ICD-10-CM, UB, CMS NCCI, etc.) when coding and billing
• Accurate documentation of services performed is required for claim adjudication

Document procedures and cytopathology interpretations consistent with listed CPT codes

Document cytopathology procedures and interpretations in the medical record consistent with the CPT codes referenced in this policy (88108, 88112, 88172, 88173, 88177) so the service, specimen technique, and interpretation are clearly supported.

• Ensure the record links the procedure performed to the appropriate code (e.g., concentration technique, liquid‑based preparation, FNA adequacy assessments)

Denial risk for cytology-based breast cancer diagnosis, screening, or risk assessment

Claims for cytologic analysis of epithelial cells (nipple aspiration, FNA, ductal lavage) to diagnose, screen for, or assess breast cancer risk do not meet criteria per this policy and may be denied.

• Cytologic analysis for diagnosis/screening/risk assessment is considered not medically necessary and at risk for denial

Procedure codes are reference only — verify appropriate coding

Procedure codes in this policy are provided as a general reference and may not be all‑inclusive; billing an inappropriate or unsupported code could affect claim processing or lead to adjudication issues.

• Policy note: procedure codes are for reference and may not cover all applicable codes
• Verify that the code billed accurately describes the service performed

Other provider responsibilities: verify benefits, include supporting documentation, and follow applicable regulations

Ensure remaining provider-action responsibilities are completed: verify member benefit coverage and Medicare/Medicaid applicability, and include documentation that justifies any requested authorization in accordance with the member’s benefit and applicable state/federal regulations.

• Confirm applicability of Medicare/Medicaid policy when conflicts exist
• Include supporting documentation with authorization requests showing medical necessity and benefit coverage
• Maintain records of cytopathology technique and interpretation consistent with billing